JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs
- PMID: 28131742
- DOI: 10.1016/j.mce.2017.01.035
JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs
Abstract
Cytokines are mediating immune cells responses through the activation of the JAK/STAT signaling pathway. Being critical for immune cells, a defective JAK/STAT signaling leads to various immune disorders, such as immunodeficiency. In contrast, hyperactivation of JAK/STAT signaling is linked to autoimmunity and cancer. Targeting the JAK/STAT proteins by small protein inhibitors impedes immune cell function by uncoupling cells from cytokine effects and by interfering with functional immune cell hallmarks, such as cell migration. This review will explore immune syndromes driven by JAK/STAT deregulation and discuss the emerging role of JAK inhibitors as immunosuppressive drugs used in autoimmunity and transplantation medicine.
Keywords: Autoimmunity; GVHD; Immunosuppression; JAK; Myeloproliferative neoplasia; STAT.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
-
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.J Cell Physiol. 2020 Sep;235(9):5903-5924. doi: 10.1002/jcp.29593. Epub 2020 Feb 18. J Cell Physiol. 2020. PMID: 32072644 Review.
-
Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.Eur J Immunol. 2017 Jul;47(7):1096-1107. doi: 10.1002/eji.201646680. Epub 2017 Jun 21. Eur J Immunol. 2017. PMID: 28555727 Review.
-
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.Drugs. 2017 Apr;77(5):521-546. doi: 10.1007/s40265-017-0701-9. Drugs. 2017. PMID: 28255960 Free PMC article. Review.
-
Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.Biochem Pharmacol. 2021 Nov;193:114760. doi: 10.1016/j.bcp.2021.114760. Epub 2021 Sep 4. Biochem Pharmacol. 2021. PMID: 34492272 Review.
-
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.Mol Cell Endocrinol. 2017 Aug 15;451:1-14. doi: 10.1016/j.mce.2017.05.033. Epub 2017 May 30. Mol Cell Endocrinol. 2017. PMID: 28576744 Review.
Cited by
-
Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma.JCI Insight. 2018 Sep 6;3(17):e120750. doi: 10.1172/jci.insight.120750. eCollection 2018 Sep 6. JCI Insight. 2018. PMID: 30185657 Free PMC article.
-
Tofacitinib reduces acute lung injury and improves survival in a rat model of sepsis by inhibiting the JAK-STAT/NF-κB pathway.J Inflamm (Lond). 2023 Feb 3;20(1):5. doi: 10.1186/s12950-023-00332-3. J Inflamm (Lond). 2023. PMID: 36737780 Free PMC article.
-
High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway.Acta Pharm Sin B. 2018 Oct;8(6):889-899. doi: 10.1016/j.apsb.2018.07.005. Epub 2018 Jul 10. Acta Pharm Sin B. 2018. PMID: 30505658 Free PMC article.
-
Tofacitinib Regulates Endostatin via Effects on CD147 and Cathepsin S.Int J Mol Sci. 2024 Jul 2;25(13):7267. doi: 10.3390/ijms25137267. Int J Mol Sci. 2024. PMID: 39000375 Free PMC article.
-
Effect of lncRNA HULC knockdown on rat secreting pituitary adenoma GH3 cells.Braz J Med Biol Res. 2019;52(4):e7728. doi: 10.1590/1414-431X20197728. Epub 2019 Apr 15. Braz J Med Biol Res. 2019. Retraction in: Braz J Med Biol Res. 2020;53(9):e7728retraction. doi: 10.1590/1414-431X20207728retraction PMID: 30994730 Free PMC article. Retracted.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
